' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 37 Researches
7.2
USERS' SCORE
Good
Based on 8 Reviews
8.5
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
†
Vitamin D3 (cholecalciferol)
10 mcg (400 IU)
67%
Total Omega-3s♦
830 mg
†
EPA (Eicosapentaenoic Acid)
205 mg
†
DHA (Docosahexaenoic Acid)
480 mg
†
Top Medical Research Studies
9
EPA's role in diabetic heart health
Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy.
High relevance to cardiovascular disease
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
8
Vitamin D improves heart disease factors
The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.
Direct relevance to cardiovascular health
We conducted a double-blind, randomized clinical trial to see how treating vitamin D deficiency could influence heart health, particularly in patients with ischemic heart disease (IHD). In our study, 44 IHD patients aged 40 to 65 were treated with either vitamin D or a placebo to assess changes in their lipid profiles and C-reactive protein (CRP) levels.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Our findings revealed that participants who received vitamin D supplementation showed notable improvements. Specifically, we observed higher levels of high-density lipoprotein cholesterol (HDL-C)—often referred to as the "good" cholesterol—and lower triglyceride levels among those treated with vitamin D. Interestingly, the increase in HDL-C and improvement in triglyceride levels underscore vitamin D’s potential role in enhancing lipid profiles in patients struggling with heart disease.
We also noted that vitamin D treatment didn’t significantly impact CRP levels, which are typically used as a marker for inflammation and heart disease risk. This suggests that while vitamin D might help improve certain lipids, its effects on other markers of heart disease need further investigation.
Overall, our study highlights the potential benefits of vitamin D supplementation as a tool to manage heart disease risk factors, offering a promising option for healthcare professionals working with patients suffering from IHD.
Read More
8
Eicosapentaenoic acid reduces coronary risk
A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events.
High relevance for cardiovascular impact
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Read More
Most Useful Reviews
8.8
Vital nutrient effect
The only DHA I prescribe for my patients, it's safe, clean, and crucial in the third trimester for fetal brain and nervous system development. For a smart baby that achieves milestones, purchase this product. Capsules are small and easy to swallow, with minimal reflux. Best taken with food for optimal absorption.
Read More
8.8
Wyeth Nutrition Brand
I have been taking omega-3 since my first trimester on my gynecologist's advice. The reliable certification of this product justified the expense. The fish oil is from wild fish, with no heavy metals or unpleasant aftertaste. It supports brain, cardiovascular, and retinal development, and has improved my skin condition. I recommend it.
Read More
8.8
Mood improvement observed
Since taking Nordic Naturals DHA during my pregnancy, I've felt more energised and my mood has improved. The high-quality capsules are easy to take, with no bad aftertaste. I feel assured my baby is receiving essential nutrients for health and development, including mitigating the risks of cardiovascular disease.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 37 Researches
7.2
9
Icosapent ethyl reduces cardiovascular risks
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Study highlights treatment effectiveness
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Read More
9
Eicosapentaenoic acid benefits heart health
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
Focus on omega-3 effects
We explored the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 polyunsaturated fatty acid (PUFA), in managing heart failure. By analyzing data from multiple randomized controlled trials, we aimed to identify the best doses and treatment durations for EPA supplementation.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
Read More
9
Krill oil may improve heart health
Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice.
Moderate relevance to research focus
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
9
EPA's role in diabetic heart health
Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy.
High relevance to cardiovascular disease
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
9
Docosahexaenoic acid improves heart function
The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.
Addresses omega-3 dosage effectiveness
We conducted a network meta-analysis to investigate the effects of docosahexaenoic acid, an omega-3 fatty acid, on heart failure management. By examining various randomized controlled trials, we aimed to understand how different dosages and durations of supplementation impact heart function.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.5
8.8
Vital nutrient effect
The only DHA I prescribe for my patients, it's safe, clean, and crucial in the third trimester for fetal brain and nervous system development. For a smart baby that achieves milestones, purchase this product. Capsules are small and easy to swallow, with minimal reflux. Best taken with food for optimal absorption.
Read More
8.8
Improved cardiovascular health
Evidence shows omega-3 acids are vital during pregnancy for fetal brain and nervous system development and help reduce the risk of cardiovascular disease. Fish oil improves immunity, supports cardiovascular function, and reduces inflammation, benefiting both the mother and child.
8.8
Wyeth Nutrition Brand
I have been taking omega-3 since my first trimester on my gynecologist's advice. The reliable certification of this product justified the expense. The fish oil is from wild fish, with no heavy metals or unpleasant aftertaste. It supports brain, cardiovascular, and retinal development, and has improved my skin condition. I recommend it.
Read More
8.8
Mood improvement observed
Since taking Nordic Naturals DHA during my pregnancy, I've felt more energised and my mood has improved. The high-quality capsules are easy to take, with no bad aftertaste. I feel assured my baby is receiving essential nutrients for health and development, including mitigating the risks of cardiovascular disease.
Read More
8.8
Healthy brain function
DHA is essential for brain health and function, with documented benefits during pregnancy and lactation. Adequate levels of DHA can positively influence the health of both mother and baby, including reducing the risk of cardiovascular disease and enhancing the development of vision.
